We Are Ananda Pharma

We're Focused on the Research and Development of CBD-based Therapies

Ananda is developing a range of cannabinoid-based medicines targeting the treatment of complex, chronic inflammatory pain conditions.

Backed By Leading Global Companies

The Opportunity For Cannabinoid Medicines

The Global Anti-Inflammatory Drugs Market Is Projected To Reach $118.4bn By 2027

We’re Developing NHS approved and MHRA licensed cannabinoid medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with CIPN & endometriosis) and HFpEF heart failure

The Ananda Pharma Approach

From Research
To Patient Delivery:
Our Process Explained

Research

Identify unmet needs where cannabinoids are shown to have clinical potential by reviewing literature, anecdotal evidence and mechanisms of action.

Development

Optimise the drug candidate and plan the route to in-human studies. Cannabinoids are well understood compounds, considered safe by the World Health Organisation so can be taken directly into Phase II and Phase III trials.

Discovery

If required, run pre-clinical animal studies to prove the proof of concept. Some indications can go straight to human trials.

Trials

Conduct clinical trials in a statistically relevant patient population, in partnership with leading researchers.

Delivery

Consult and coordinate with regulators to achieve MHRA/ FDA/EMA/etc marketing authorisations and secure access to national health services and confirm reimbursement plans with private healthcare providers.

Our Approach

Transforming Lives Through Cannabinoid Medicines

We believe that cannabidiol, with its multiple molecular and cellular mechanisms of action has the potential to become a crucial element in the treatment plans for many complex conditions, especially in chronic pain and inflammatory indications.

The Ananda Pharma Board Of Directors

Professionals With A Personal Investment

Our Board of Directors

Charles Morgan
Chairman

Charles Morgan is a resources and technology venture capitalist who has identified emerging sectors and acquired early stage and strategic positions in a wide range of ventures around the globe.

Read More
Melissa Sturgess
Chief Executive Officer

Melissa Sturgess holds a BSc and an MBA and has more than 20 years of experience as a director of UK and Australian Stock Exchange quoted companies, in the roles of Chair, CEO and non-executive director.

Read More
Stuart Piccaver
Non-Executive Director

Stuart, in his role as CEO of JEPCO, has considerable horticultural experience and direct experience of Cannabis cultivation and has been the driving force for many of the leading agricultural initiatives and successes of JEPCO and its associated companies.

Read More
Jeremy Sturgess-Smith
Finance Director

Jeremy Sturgess-Smith is a finance leader with a proven track record in corporate finance, investor relations, and strategic growth.

Read More
John Treacy
Independent Non-Executive Director

Mr Treacy is an experienced London-based small cap financier who specialises in working with growing companies. He qualified as a solicitor in the London office of a major international law firm where he specialised in Capital Markets and Mergers & Acquisitions.

Read More
Professor Clive Page
Non-Executive Director

Clive Page is a Professor of Pharmacology, King’s College London and Director of The Pulmonary Pharmacology Unit, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory diseases, and he has published over 250 scientific papers.

Read More

You can read more about each of our board members on our board of directors page.

Invest In Our Future Success